Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI
Study Details
Study Description
Brief Summary
Gilles de la Tourette syndrome (GTS; also known as Tourette syndrome) is a congenital neuropsychiatric disorder. Characteristic symptoms are so-called tics-rapid, repetitive movements (motor tics) or vocalizations (vocal tics) that start suddenly without any apparent purpose. Previous research supports the hypothesis of defective regulation (dysregulation) of the dopaminergic system, with particular discussion of dysfunction of tonic/phasic dopamine release or dopaminergic hyperinnervation. Moreover, given the complex interaction of different neurotransmitters, especially in the basal ganglia, it can be assumed that abnormal dopaminergic transmission also affects other transmitter systems, such as glutamate (Glu) or γ-aminobutyrate (GABA). Furthermore, recent results suggest an abnormality in cerebral iron metabolism in GTS. Since iron is accumulated in dopamine vesicles and plays a central role in dopamine synthesis, this observation may also be related to dysfunction of the dopaminergic system. Therefore, in this multimodal study, the investigators aim to combine positron emission tomography (PET), magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) methods comparing patients with GTS and a control cohort.
In Part 1 of this study, MRI and MRS at 3 Tesla are employed to investigate (i) the binding potential of D1 dopamine receptors, (ii) the concentrations of Glu, glutamine and GABA in the corpus striatum and the cortex cingularis anterior and (iii) the subcortical iron concentration.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
State of the Art
Gilles de la Tourette Syndrome (GTS) is characterized by the presence of motor and vocal tics, which have been defined as rapid, habitual, burst-like movements or utterances that typically mimic fragments of normal behavior. Patients often report unpleasant premonitory urge sensations preceding tics that are relieved by their execution. Although the therapeutic spectrum for GTS has recently been expanding, current treatment strategies are often unsatisfactory, thus provoking the need for further elucidation of the underlying pathophysiology.
In current models of GTS pathophysiology, symptoms are thought to arise as a result of the inappropriate activation of specific clusters of striatal neurons, which lead to a burst-like disinhibition of thalamocortical output. The bulk of current literature suggests a dysregulated dopaminergic system. This is supported by clinical evidence of improvements in tics following the administration of dopamine antagonists, synthesis blockers or depletion drugs, and the exacerbation of symptoms following the administration of dopaminergic stimulants. Dopamine drives movement by activating a direct, net excitatory basal ganglia pathway involving the dopamine receptor D1 or an indirect, net inhibitory basal ganglia pathway involving the dopamine receptor D2. Currently, the vast majority of the antipsychotics used for the treatment of tics in GTS aim at the D2 receptor, with aripiprazole, risperidone and pimozide being selective D2 receptor antagonists and haloperidol being mainly a D2 receptor antagonist. However, recent randomized controlled trials further indicate promising results for the selective dopamine receptor D1 antagonist ecopipam.
Methodologically varied work has revealed that patients with GTS exhibit alterations in (i) D2 receptor density or binding, (ii) Dopamine Active Transporter (DAT) density/binding, and (iii) phasic dopamine transmission in striatal and cortical regions. A very small number of post-mortem examinations further suggest potential abnormalities in D1 (and D2 and DAT) receptor densities in cortical regions. While this would be in line with the therapeutic efficiency of selective D1 receptor antagonists, thorough experimental verification is missing. In particular, D1 receptors in GTS patients have not yet been investigated in vivo, suggesting a need for additional research.
Both postsynaptic and presynaptic mechanisms have been postulated to offer explanations of the above observations:
-
Supersensitive postsynaptic dopamine receptors were proposed, in particular to explain findings of reduced levels of homovanillic Acid (HVA) in cerebrospinal fluid (CSF) in GTS despite the premise of a hyperdopaminergic system. The validity of this view has been questioned as HVA levels may be confounded by medication, and previous positron emission tomography (PET) studies on dopamine receptors (although likely involved in the neurobiology of GTS) have produced inconsistent results.
-
Dopamine hyperinnervation, that is, an overabundance of striatal dopamine terminals was suggested to reflect observations of generally increased binding to the DAT and to the vesicular monoamine transporter type 2 (VMAT2).
-
Tonic-phasic dysfunction assumes reduced tonic dopamine levels as well as a hyperresponsive (spike-dependent) phasic dopaminergic system. A low tonic dopamine tone could be caused by an overactive DAT preventing efficient spillage to the extrasynaptic space and/or altered presynaptic dopamine D2 autoreceptor binding.
Apart from such considerations specific to dopamine one can postulate that if a dopaminergic abnormality were present, other neurotransmitter systems would exhibit perturbations as well. In particular, this is suggested by (i) the close synergy exhibited between excitatory, inhibitory and modulatory neurotransmitter systems within the striatum and throughout the brain; and (ii) the interdependent metabolic relationship exhibited between glutamate (Glu), and γ-aminobutyric acid (GABA) via the non-neuroactive metabolic intermediate glutamine (Gln). Moreover, an irregular afferent modulation of dopaminergic nuclei would have profound effects on tonic/phasic dopaminergic release in the striatum and the control of subsequent thalamocortical output. Consistently, separate groups have demonstrated that adult patients with GTS exhibit alterations within the GABAergic system in cortical regions using in vivo proton (1H) magnetic resonance spectroscopy (MRS) and subcortical regions using PET. Employing 1H MRS, the investigators recently found reductions in striatal concentrations of Gln and the sum of Glu plus Gln (Glx) in GTS patients as well as negative correlations between striatal Gln and actual tic severity and between thalamic Glu and premonitory urges. While these findings do not rule out alternative mechanisms, they lend support to the hypothesis of an alteration in the dynamics of the tonic/phasic dopaminergic signaling because chronic perturbations in the subcortical GABA-Glu-Gln cycle flux could lead to spatially focalized alterations in excitatory and inhibitory neurotransmitter ratios.
Another aspect of dopamine neurobiology that has recently gained interest in the context of neuroimaging is the relation to brain iron. Besides supporting myelination and cellular respiration, brain iron is crucial for the synthesis of neurotransmitters, in particular dopamine. It is stored primarily as ferritin and co-localizes with dopamine vesicles having the greatest concentration in the dopamine-rich basal ganglia and midbrain. As the major brain iron compounds have (super)paramagnetic properties, they can be detected via susceptibility-sensitive magnetic resonance (MR) techniques, such as quantitative susceptibility mapping (QSM) or measurements of the effective or the reversible transverse relaxation rates, R2* or R2', respectively. Recent multimodal imaging targeted at (normal) developmental changes of the striatal dopamine system demonstrated that R2'-based estimates of tissue iron content were associated with carbon-11 [11C]dihydrotetrabenazine PET of presynaptic vesicular dopamine. This suggests that susceptibility-sensitive MR imaging (MRI), which does not require an intravenously applied radiotracer, might serve as a proxy for obtaining information on dopamine that could substitute measurements of HVA in CSF without sharing the same confounds. More recently, the investigators already obtained preliminary indications of disturbed iron homeostasis in GTS patients as evidenced by reduced serum ferritin and magnetic susceptibility in the striatum and further subcortical structures.
Objectives and Hypotheses
In continuation of previous investigations, the investigators plan to perform examinations with MRI and MRS in GTS patients in comparison to age- and sex-matched healthy controls within Part 2 of this combined study. This includes (indirect) information on the interplay of different neurotransmitter systems (Glu, and GABA), as well as on the role of brain iron in GTS.
In particular, the investigators plan to use (i) iron-sensitive MRI techniques, such as QSM and R2* mapping, for obtaining indirect information on presynaptic dopamine availability; (ii) [11C]SCH23390 PET measures of cortical D1 receptor binding/densities in vivo in GTS patients; and (iii) 1H MRS with standard single-voxel techniques and spectral-editing methods, for obtaining neurochemical profiles and quantitative information on Glu, Gln, and GABA in the striatum and cortical areas.
Neuropsychological tests:
At the time of the MR and/or PET exams, an established, comprehensive test battery will be performed with all patients for a detailed clinical assessment, including the severity of tics or the presence of comorbidities. These tests may be performed online as a video conference questionnaire and include:
-
DSM-IV-symptom list for attention deficit hyperactivity disorder (ADHD), rage attack questionnaire (RAQ), Pittsburgh sleep quality index (PSQI);
-
Clinical ratings : Yale global tic severity scale (YGTSS-R), Yale-Brown obsessive-compulsive scale (Y-BOCS), clinical global impression scale (CGI).
-
Self-assessment questionnaires: adult tic questionnaire (ATQ), Beck depression inventory (BDI), Beck anxiety inventory (BAI), Conners' adult ADHA rating scales (CAARS), autism spectrum quotient (AQ); premotory urge for tics scale (PUTS), GTS quality of life scale (GTS-QOL).
MR exams within Part 1 (Simultaneous PET and 3T MR):
PET investigations of D1 receptor binding/density will be performed with the 11C-based tracer [11C]SCH23390, which has already revealed abnormalities in cortical D1 receptor in other neuropsychiatric disorders. Before starting the PET measurement, the subject is positioned on the scanner's patient table and asked to relax for several minutes while an intravenous line is in-serted into an arm vein for injection of the radionuclide. Subsequently, [11C]SCH23390 is administered during 90 s following established procedures for the specific radionuclide. The administered radioactivity varies around 500 MBq, depending on the specific activity and the subject's body mass. Following injection, dynamic emission data are collected for approx. 90 min. The acquired frames (4 during 15 s, 4 during 1 min, 5 during 2 min, 5 during 5 min, and 5 during 10 min) are reconstructed into a series of three-dimensional (3D) PET images for evaluations of the D1 receptor distribution volume ratio and binding potential.
Simultaneous MR scanning at 3 Tesla (3 T) will be performed during PET scanning. These acquisitions are based on a protocol that has been established in previous investigations of
GTS patients comprising the following acquisitions:
-
Scout acquisition for automated alignment of imaging or spectroscopy volumes ("auto align").
-
Structural MR scan ("MP2RAGE") for image registration, tissue segmentation, morphometry of cortical and subcortical structures, and for measuring the longitudinal relaxation time T1 to obtain information on myelin and brain iron content.
-
Susceptibility-sensitive acquisition ("multi-echo FLASH") for measurements of the magnetic susceptibility (QSM) and R2* to obtain information on brain iron and myelin.
-
Single-voxel proton MRS of the basal ganglia and the anterior cingulate cortex to measure metabolic profiles, in particular to obtain concentration estimates of local Glu and Gln (or Glx).
-
Resting-state functional MRI acquisition to extract information on functional connectivity.
-
Diffusion-weighted MRI to extract information on structural connectivity. The total time for the combined PET/MR acquisitions including preparations and patient positioning will not exceed 100 min. From all subjects (GTS patients and healthy controls) 10ml of venous blood will be collected at the time of the exam for subsequent measurement of blood ferritin levels. These levels will be compared with the results from susceptibility-related measures of brain iron.
10ml of venous blood will be collected from all subjects (GTS patients and healthy controls) at the time of the exam for subsequent measurement of blood ferritin levels. These levels will be compared with the results from susceptibility-related measures of brain iron.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| GTS patient group Cohort of adult GTS patients, males and females, age range 18 to 50 years |
Device: PET/MR scanner
Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
|
| Control group Cohort of healthy control subjects, males and females, age range 18 to 50 years |
Device: PET/MR scanner
Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
|
Outcome Measures
Primary Outcome Measures
- D1 receptor availability [D1 receptor availability is measured at the time of the PET/MR exam]
GTS patients exhibit reduced tonic levels of dopamine and, in particular in frontal brain, abnormalities in D1 receptor availability
- Subcortical magnetic susceptibility as brain iron proxy [Susceptibility is measured at the time of the PET/MR exam]
Iron stores in subcortical structures are reduced in GTS patients
- Concentration of glutamate (Glu) and glutamate plus glutamine (Glx) [Glu and Glx are measured at the time of the PET/MR exam]
Glu and Glx levels are reduced in GTS patients in striatum
- Concentration of glutamine (Gln) [Gln is measured at the time of the PET/MR exam]
Gln levels are reduced in GTS patients in striatum
- Concentration of γ-aminobutyrate (GABA) [GABA is measured at the time of the PET/MR exam]
GABA levels in GTS patients deviate from those in healthy controls in striatum and cingulate cortex
Secondary Outcome Measures
- Plasma ferritin level [A plasma sample is taken at the time of the PET/MR exam]
Blood ferritin is reduced in GTS patients
Eligibility Criteria
Criteria
GTS Group:
Inclusion Criteria:
-
GTS according to DSM-IV-TR criteria
-
mild or moderate tics
-
drug-free for a minimum of 4 weeks prior to the exam
Exclusion Criteria:
-
severe tics of the head and/or face
-
psychiatric medication within 4 weeks prior to the exam
-
consumption of alcohol during 24 hours prior to the exam
-
consumption of cannabis during 24 hours prior to the exam • pregnancy
-
general contra-indications for MRI exams
Control Group:
Inclusion Criteria:
• no known neurological or psychiatric disease
Exclusion criteria:
-
psychiatric medication within 4 weeks prior to the exam
-
consumption of alcohol during 24 hours prior to the exam
-
consumption of cannabis during 24 hours prior to the exam • pregnancy
-
general contra-indications for MRI exams
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Max Planck Institute for Human Cognitive and Brain Sciences | Leipzig | Germany | 04103 |
Sponsors and Collaborators
- Max Planck Institute for Human Cognitive and Brain Sciences
- Leipzig University Medical Center
- Hannover Medical School
Investigators
- Principal Investigator: Harald E Möller, PhD, Max Planck Institute for Human Cognitive and Brain Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
- Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci. 2006 Mar;29(3):175-82. Epub 2006 Jan 23. Review.
- Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001 Winter;7(4):399-414. Review.
- Draper A, Stephenson MC, Jackson GM, Pépés S, Morgan PS, Morris PG, Jackson SR. Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol. 2014 Oct 6;24(19):2343-7. doi: 10.1016/j.cub.2014.08.038. Epub 2014 Sep 25.
- Forde NJ, Kanaan AS, Widomska J, Padmanabhuni SS, Nespoli E, Alexander J, Rodriguez Arranz JI, Fan S, Houssari R, Nawaz MS, Rizzo F, Pagliaroli L, Zilhäo NR, Aranyi T, Barta C, Boeckers TM, Boomsma DI, Buisman WR, Buitelaar JK, Cath D, Dietrich A, Driessen N, Drineas P, Dunlap M, Gerasch S, Glennon J, Hengerer B, van den Heuvel OA, Jespersgaard C, Möller HE, Müller-Vahl KR, Openneer TJ, Poelmans G, Pouwels PJ, Scharf JM, Stefansson H, Tümer Z, Veltman DJ, van der Werf YD, Hoekstra PJ, Ludolph A, Paschou P. TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. Front Neurosci. 2016 Aug 23;10:384. doi: 10.3389/fnins.2016.00384. eCollection 2016.
- Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 Aug;33(8):1272-1280. doi: 10.1002/mds.27457. Epub 2018 Sep 7.
- Kaller S, Rullmann M, Patt M, Becker GA, Luthardt J, Girbardt J, Meyer PM, Werner P, Barthel H, Bresch A, Fritz TH, Hesse S, Sabri O. Test-retest measurements of dopamine D(1)-type receptors using simultaneous PET/MRI imaging. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1025-1032. doi: 10.1007/s00259-017-3645-0. Epub 2017 Feb 14.
- Kanaan AS, Gerasch S, García-García I, Lampe L, Pampel A, Anwander A, Near J, Möller HE, Müller-Vahl K. Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. Brain. 2017 Jan;140(1):218-234. doi: 10.1093/brain/aww285. Epub 2016 Dec 22.
- Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec;18(12):1530-3.
- Larsen B, Olafsson V, Calabro F, Laymon C, Tervo-Clemmens B, Campbell E, Minhas D, Montez D, Price J, Luna B. Maturation of the human striatal dopamine system revealed by PET and quantitative MRI. Nat Commun. 2020 Feb 12;11(1):846. doi: 10.1038/s41467-020-14693-3.
- Leckman JF. Tourette's syndrome. Lancet. 2002 Nov 16;360(9345):1577-86. Review.
- Lerner A, Bagic A, Simmons JM, Mari Z, Bonne O, Xu B, Kazuba D, Herscovitch P, Carson RE, Murphy DL, Drevets WC, Hallett M. Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain. 2012 Jun;135(Pt 6):1926-36. doi: 10.1093/brain/aws104. Epub 2012 May 10.
- Maia TV, Conceição VA. Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account. Biol Psychiatry. 2018 Sep 1;84(5):332-344. doi: 10.1016/j.biopsych.2018.02.1172. Epub 2018 Mar 9. Review.
- Mink JW. Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. Pediatr Neurol. 2001 Sep;25(3):190-8. Review.
- Möller HE, Bossoni L, Connor JR, Crichton RR, Does MD, Ward RJ, Zecca L, Zucca FA, Ronen I. Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. Trends Neurosci. 2019 Jun;42(6):384-401. doi: 10.1016/j.tins.2019.03.009. Epub 2019 Apr 29. Review.
- Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 1997 Feb 13;385(6617):634-6.
- Singer HS, Morris C, Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses. 2010 May;74(5):862-7. doi: 10.1016/j.mehy.2009.11.028. Epub 2009 Dec 21.
- Singer HS. Treatment of tics and tourette syndrome. Curr Treat Options Neurol. 2010 Nov;12(6):539-61. doi: 10.1007/s11940-010-0095-4.
- Tinaz S, Belluscio BA, Malone P, van der Veen JW, Hallett M, Horovitz SG. Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging. Hum Brain Mapp. 2014 Dec;35(12):5834-46. doi: 10.1002/hbm.22588. Epub 2014 Jul 15.
- Yoon DY, Gause CD, Leckman JF, Singer HS. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci. 2007 Apr 15;255(1-2):50-6. Epub 2007 Mar 6.
- PETMR_GTS_1-PETMR